A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)
Brief description of study
The purpose of this trial is to evaluate the safety, tolerability, and efficacy of
pembrolizumab (MK-3475) in hematologic malignancies (myelodysplastic syndrome [MDS],
multiple myeloma [MM], Hodgkin's lymphoma [HL], mediastinal large B cell lymphoma [MLBCL],
and non-Hodgkin's lymphoma [NHL]).
Clinical Study Identifier: NCT01953692